Neil Kumar - Nov 16, 2022 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Nov 16, 2022
Transactions value $
-$654,002
Form type
4
Date filed
11/18/2022, 05:42 PM
Previous filing
Aug 18, 2022
Next filing
Dec 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise +68.7K +1.43% 4.88M Nov 16, 2022 Direct F1
transaction BBIO Common Stock Tax liability -$328K -34.1K -0.7% $9.64 4.85M Nov 16, 2022 Direct F2
transaction BBIO Common Stock Sale -$326K -34.6K -0.71% $9.40 4.81M Nov 17, 2022 Direct F3
holding BBIO Common Stock 1.61M Nov 16, 2022 See Footnote F4
holding BBIO Common Stock 1.2M Nov 16, 2022 See Footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Restricted Stock Units Options Exercise $0 -5.13K -14.29% $0.00 30.8K Nov 16, 2022 Common Stock 5.13K Direct F1, F6
transaction BBIO Restricted Stock Units Options Exercise $0 -2.39K -10% $0.00 21.5K Nov 16, 2022 Common Stock 2.39K Direct F1, F7
transaction BBIO Restricted Stock Units Options Exercise $0 -61.2K -16.67% $0.00 306K Nov 16, 2022 Common Stock 61.2K Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 68,706 shares of Common Stock underlying the Reporting Person's RSUs.
F3 Represents the weighted average sale price of the shares sold from $9.16 to $9.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.
F4 The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F5 The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F6 The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
F7 The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
F8 The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.